Counteracting high failure rates in the development of new treatment strategies in oncology requires preclinical models that can account for the complexity and heterogeneity of human tumours. Patient-derived tumour xenografts (PDXs) are widely recognized as clinically relevant preclinical models, as they maintain histopathological features and genetic profiles of original patient tumours. Many PDXs have been established across Europe.
In 2013, cancer researchers in Europe established the EurOPDX Research Infrastructure to mutualise efforts, share expertise, and avoid duplication in preclinical oncology research. Their first meeting attracted 14 cancer centres and universities across nine European countries, proving the shared value of collaboration and laying the groundwork for building a Research Infrastructure to improve outcomes in preclinical cancer research.
Centred in Europe, this cutting-edge infrastructure offers access to PDX resources for academic and industrial cancer researchers worldwide. Important aspects of the project include the integration and curation of a large collection of established PDX models, as well as efforts to raise standards in preclinical settings.
As the exclusive breeder and distributor of JAX™ Mice in Europe, Charles River will supply the consortium with the NSG® mouse, a crucial, core component of its PDX-based oncology research. The triple-immunodeficient JAX™ NSG® mouse will be used for all biobanking and in vivo drug efficacy studies under the project.